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Abstract
Opioid-induced bowel dysfunction (OIBD) and opioid-induced constipation (OIC) significantly decrease 
patients’ quality of life (QoL), lead to complications and opioid non-compliance resulting in pain exac-
erbation. Traditional laxatives are first-line preventive and therapeutic measures, although they display 
limited efficacy and several adverse effects (AE). Non-pharmacology measures, prokinetics, opioid switch, 
all have little evidence and do not target OIBD and OIC pathophysiology both associated with activation 
of predominantly µ-opioid receptors mostly peripherally in the gastrointestinal (GI) tract. A combination of 
prolonged-release (PR) oxycodone with PR naloxone in one tablet with a ratio of 2:1 is available, although 
limitations include maximal daily dose of 160 mg/80 mg, respectively, and normal liver function.
Peripherally acting µ-opioid receptor antagonists (PAMORA) block opioid receptors in the GI tract without 
compromising analgesia as they do not cross the blood–brain barrier. Currently three drugs are available: 
methylnaltrexone, naloxegol and naldemedine.
Naldemedine has proven efficacy superior to placebo in the treatment of OIC in both cancer and non-cancer 
patients while improving patient-reported constipation symptoms and patients’ QoL. It is well tolerated 
with mostly mild to moderate intensity GI adverse effects such as abdominal, pain, nausea, and diarrhea, 
without compromising analgesia. Naldemedine dosing is convenient as it is administered once daily by an 
oral route. Moreover, naldemedine may be safely used in patients with renal failure and mild to moderate 
hepatic impairment. Effective prevention and treatment of OIC is of paramount importance in patients 
receiving long-term opioid therapy.
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Introduction
Opioid-induced constipation
Opioids are invaluable drugs for the management 
of chronic severe pain but may also induce numerous 
adverse effects (AE). Tolerance develops for some of 
opioid centrally-mediated AE, such as sedation, but 
often there is little or no tolerance development to 
peripheral opioid AE including those affecting gas-
trointestinal (GI) tract function, opioid-induced bowel 
dysfunction (OIBD). The most common and usually 
most burdensome for patients symptoms of OIBD 
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are called opioid-induced constipation (OIC), which is 
defined as decreasing number of bowel movements 
but more importantly subjective symptoms experi-
enced by patients associated with initiating, changing 
or increasing opioid use. OIBD reflexes the impact 
of opioids on the whole GI tract, which comprises 
such symptoms as dry mouth, gastro-esophageal 
reflux-related symptoms (heartburn), nausea, vom-
iting, chronic abdominal pain, bloating, constipa-
tion-related symptoms: straining, hard stools, painful, 
infrequent and incomplete bowel movements, and 
diarrhea-related symptoms: urgency, loose bowel 
movements and frequent bowel movements. OIBD 
and OIC may significantly decrease patients’ quality 
of life (QoL) and lead to non-compliance with opioid 
regimen resulting in undertreatment of chronic pain. 
Patients should be closely monitored by the staff to 
prevent or decrease the intensity of OIBD and OIC. 
OIBD and OIC are frequent phenomenon with the 
incidence of approximately 40–80% patients receiving 
chronic opioid therapy in both cancer and non-cancer 
patients [1].
OIBD is associated mainly with the peripheral opi-
oid effect on µ–opioid receptors in the gut wall with 
probably less central effects. The µ-opioid receptors 
are located in neurons of myenteric and submucosal 
plexus. The myenteric plexus is mainly responsible for 
the control of motor activity of the gut. The submu-
cosal plexus controls the secretion and absorption; 
µ-opioid receptors are activated in the wall of the 
stomach, small and large intestine by endogenous 
and exogenous opioids. Activation of µ-opioid recep-
tors decreases peristaltic contractions and increases 
GI muscle activity and elevates resting muscle tone, 
spasm and non-propulsive motility patterns. These 
mechanisms induce delayed gastric emptying and 
slow intestinal transit. Additionally opioids increase 
anal sphincter tone and impair rectal relaxation with 
distention Opioids increase ileocecal and anal sphinc-
ter tones and impair defecation reflex through re-
duced sensitivity to distension and increased internal 
anal sphincter tone which may disturb pelvic floor 
coordination during defecation. The anal sphincter 
dysfunction is an important factor in the sensation 
of anal blockage. All these abnormalities result in 
an increased segmental contraction along with de-
creased propulsive forward peristalsis. Clinically, these 
changes manifest as constipation, gut spasm and 
abdominal cramps. A consequence of this peristaltic 
disruption is stasis of luminal contents, which leads 
to an increased passive absorption of fluids, dryer and 
harder stools [2].
Clinical assessment of patients with symptoms of 
OIBD and OIC is necessary for the application of effec-
tive treatment. It is composed of a detailed history that 
should include GI symptoms, other physical problems, 
psychological and spiritual issues. Physical examina-
tion includes palpation of abdomen, auscultation of 
peristalsis and rectal examination. Acute abdominal 
diseases should be excluded such as bowel obstruc-
tion or gut perforation. Investigations comprise plain 
radiography, transit time studies, manometry, and 
anorectal dysfunction tests. However, apart from plain 
radiography, these investigations are rarely used in 
palliative care patients [3].
The most commonly use subjective scale is the 
Bowel Function Index (BFI). The BFI is a three-item 
questionnaire that assesses the severity of ease of 
defecation, felling of incomplete bowel evacuation, 
and patients’ personal judgment of constipation us-
ing a 0 to 100 numerical rating (0 — no symptom, 
100 — the most severe symptom). Patients rate these 
variables of the preceding 7 days. The BFI score 
is calculated as the mean of the three component 
scores. Reference results of non-constipated chron-
ic pain patients BFI scores lie within the range of 
0–28.8. The BFI was validated in several clinical studies 
conducted in cancer and non-cancer patients. Changes 
in BFI scores equal or above 12 are likely to be clini-
cally meaningful and those lower than 7.5 unlikely to 
be clinically relevant, with changes between 7.5 and 
12 not clear that require further evaluation [4].
The Patient Assessment of Constipation includes 
the symptom questionnaire (PAC-SYM) and the quality 
of life questionnaire (PAC-QOL). The PAC-SYM contains 
12 items assigned to three subscales: stool symptoms, 
rectal symptoms, and abdominal symptoms. PAC-SYM 
also contains a question about the frequency of bowel 
movements during the last 7 days [40–9]. The PAC-
QOL is composed of 28 items grouped into 4 subscales 
related to dissatisfaction (5 items), physical discom-
fort (4 items), psychosocial discomfort (8 items), and 
worries and concerns (11 items). Validation studies 
have confirmed that PAC-QOL is internally consistent, 
reproducible, valid, and responsive to improvements 
over time [5]. The objective assessment comprises the 
Bristol Stool Chart — a simple and easy to use meth-
od evaluating stool frequency and stool consistency. 
However, only a moderate correlation between stool 
form and whole-gut or colonic transit time can be 
demonstrated [6].
Management of opioid-induced 
constipation
Non-pharmacological measures
Non-pharmacological measures may be consid-
ered throughout a whole period of care and play 
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an important role in the prevention of OIBD and OIC 
development. This may include ensuring privacy and 
comfort to allow a patient to defaecate normally, 
appropriate positioning (to assist gravity, a small 
footstool may help patient exert pressure more eas-
ily), increased fluid intake, encourage activity and 
increased mobility within patient limits (even bed to 
chair), anticipatory management of constipation when 
opioids prescribed, advise against home remedies 
or “over the counter” or online products which may 
impact treatments. An important role of education 
of patients’ and careers should be emphasized [1].
Prokinetics
Itopride is a peripheral antidopaminergic agent 
that also increases acetylocholine level due to the 
inhibition of acetylocholinesterase and the prokinetic 
effect observed in the whole GI tract. It does not acti-
vate 5-HT4 nor 5-HT3 receptors. Itopride displays little 
risk of significant pharmacokinetic interactions with 
other drugs. It does not permeate the blood–brain 
barrier and poses no risk of extra-pyramidal effects 
[7]. The recommended dose is usually 50 mg three 
times daily.
Prucalopride is a selective 5HT4 receptor agonist 
which stimulates propulsive gut motility. Prucalopride 
accelerates the whole gut, gastric, small bowel and 
colonic transit in patients with chronic constipation 
[8]. The recommended dose is usually 2 mg once 
daily. Prucalopride was introduced for the treatment 
of chronic constipation, predominantly in women 
[9]. Itopride and prucalopride do not display cardi-
ac toxicity.
Lubiprostone activates type-2 chloride channels 
and increases intestinal fluid secretion, thereby facil-
itating intestinal transit and increasing the passage 
of stool [10]. Lubiprostone is registered by the FDA 
for the management of OIBD in patients with chronic 
non-malignant pain. The most common AE comprised 
nausea (11% of treated patients), diarrhea (8%), 
and abdominal pain (4%). However, in contrast to 
morphine lubiprostone may be ineffective in patients 
treated with methadone [11].
Linaclotide is an agent that regulates chloride 
secretion on the intestinal epithelial cells through 
activation of guanylate cyclase C. Linaclotide stim-
ulates the GI secretion and transit and also modu-
lates visceral sensitivity. It increases stool frequen-
cy, stool weight and improves the ease of stool 
passage. The main AE of linaclotide is diarrhea 
[12]. Linaclotide may be potentially considered 
for the management of OIBD although it is used 
in patients with chronic constipation and irritable 
bowel syndrome [13].
Laxatives
Numerous laxatives are prescribed for the preven-
tion and treatment of OIBD, particularly for consti-
pation-related symptoms. The most commonly used 
group of laxatives for OIBD comprise osmotic agents 
and stimulants. Nonetheless, they possess limited 
efficacy not proven in RCT and display their own AE 
[14]. Moreover, treatment with laxatives should be 
limited to a short period of time. Patients with chronic 
non-malignant and cancer-related pain usually have 
to take laxatives for the long-term [15].
Rectal measures
Suppositories and enemas are a preferred first-line 
therapy when digital rectal examination identifies 
a full rectum or fecal impaction. Suppositories and 
enemas may be perceived as a more invasive option 
by patients. Enemas (such as hyperosmotic saline) and 
suppositories increase water content and stimulate 
peristalsis to aid in expulsion, and both work more 
quickly than oral laxatives. In general, enemas are used 
only if oral treatment fails after several days and in 
order to prevent fecal impaction [2].
Change of opioid route of administration and 
opioid rotation (switch)
A change from oral to parenteral or to transdermal 
route of opioid administration may be considered. 
However, all opioids display OIBD including transder-
mal formulations. A switch from hydrophilic opioids 
(morphine, oxycodone, hydromorphone) to lipophylic 
drugs (fentanyl, buprenorphine, methadone) due to 
less peripheral effects of the latter may be considered, 
although the evidence is limited [1].
Combination of opioid receptors agonist with 
opioid receptors antagonists
Newer strategies for the management of OIBD in-
clude administration of a combination of prolonged-re-
lease (PR) oxycodone with PR naloxone (OXN) in one 
tablet. OXN renders analgesia with limited negative 
effect of oxycodone on bowel function. Naloxone dis-
play very low systemic availability (approximately 2%) 
after oral administration of PR formulation. However, 
limitations of OXN use include maximal daily dose of 
160 mg/80 mg of oxycodone and naloxone, respective-
ly, and a requirement of a normal liver function and 
portal circulation necessary to avoid significant systemic 
availability and the risk of opioid withdrawal [16].
Peripherally acting µ-opioid receptor antagonists
Treatment with opioid receptor antagonists that 
act purely peripherally may be used when traditional 
oral laxatives fail.
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Methylnaltrexone
MNTX is a quaternary methyl derivative of naltrex-
one, preferential, non-selective, peripheral µ-opioid 
receptor antagonist. The addition of the methyl group 
to the nitrogen ring increases polarity and reduces 
lipophilicity of MNTX. As a consequence, MNTX does 
not cross the blood–brain barrier and displays limited 
absorption from the gut. When administered system-
ically (orally, subcutaneously, intravenously), MNTX 
does not reverse opioid analgesia, which is the case 
for MNTX intrathecal administration [17].
MNTX is effective in palliative care patients with 
OIC when conventional laxatives have failed. A system-
atic review and meta-analysis of 14 controlled studies 
including 4101 patients demonstrated superiority 
of mu-opioid receptor antagonists over placebo in 
the treatment of OIC. MNTX, naloxone and alvimo-
pan (used only for up to 48 hours in the treatment 
of postoperative ileus due to the risk of cardiotox-
icity) all were superior to placebo. AE (diarrhea and 
abdominal pain) were more common during these 
drugs administration compared to placebo. Reversal 
of analgesia was not observed during active therapy. 
Lubiprostone was beneficial in two controlled studies 
and prucalopride showed a tendency of a better re-
sponse in one study but the meta–analysis could not 
be conducted [18].
MNTX dosing (a single dose administered by subcu-
taneous route equals 8–12 mg depending on the body 
weight) is similar in younger and older patients. No 
dose adjustment is required in patients with mild to 
moderate renal impairment. However, in patients 
with renal failure (creatinine clearance < 30 mL/min) 
the MNTX dose should be reduced by one-half. No 
dose adjustment is required for patients with mild to 
moderate hepatic impairment. MNTX is not recom-
mended for patients with end-stage renal impairment 
requiring dialysis and for patients with severe liver 
impairment [17].
It is recommended that MNTX should be used 
with caution in patients with present or suspected 
lesions of the GI tract. Treatment with MNTX should 
be stopped if severe abdominal symptoms appear or 
intensify. If severe or persistent diarrhea occurs during 
the treatment, patients are advised to discontinue 
the MNTX therapy. Clinical studies demonstrated the 
effectiveness of MNTX in the treatment of OIC not 
responding to traditional laxatives in patients with 
advanced diseases, non-malignant pain [17].
Naloxegol
Naloxegol is a polymer conjugate of the opioid an-
tagonist naloxone administered once daily by the oral 
route. The polyethylene glycol moiety limits naloxegol 
capacity to cross the blood-brain barrier. In a phase 
2, randomized, double-blind, placebo-controlled, 
dose-escalation study, the efficacy and safety of three 
dose levels of oral naloxegol in the treatment of OIC 
in patients with non-malignant or cancer-related pain 
was evaluated. The dose of 25 mg naloxegol was 
chosen to be further explored in phase 3 studies [19].
Naloxegol is metabolised through CYP3A4 to six 
metabolites, with the majority of the dose (68%) ex-
creted with faeces and less (16%) with urine. The dose 
of naloxegol equals 25 mg administered orally once 
daily on a fasting condition. Mild or moderate hepatic 
impairment has no impact on naloxegol dosing; na-
loxegol was not studied and is not recommended in 
patients with hepatic failure. Dose reduction (12.5 mg 
once daily) and caution is recommended in patients 
with moderate-to-severe renal impairment. Efficacy 
measured as bowel movement (BM) was noted in 
42–49% of patients not responsive to laxatives. Safety 
of naloxegol were confirmed in studies conducted in 
patients with OIC and non-malignant pain.
Two phase-3, double-blind clinical studies (KO-
DIAC-04 and KODIAC-05) have been completed and 
demonstrated significant increase in spontaneous 
bowel movements (SBM) compared to placebo for 
the 25-mg naloxegol dose (in one study also for 
the 12.5-mg dose), with arthralgia as the only AE 
more common than in the placebo group [20]. In 
both studies (study 04, 652 participants; study 05, 
700 participants), outpatients with non-cancer pain 
and OIC were randomly assigned to receive a daily 
dose of 12.5 or 25 mg of naloxegol or placebo. The 
primary end point was the 12-week response rate 
(≥ 3 SBM per week and an increase from baseline 
of ≥ 1 SBM for ≥ 9 of 12 weeks and for ≥ 3 of the 
final 4 weeks) in the intention-to-treat population. 
The key secondary end points were the response rate 
in the subpopulation of patients with an inadequate 
response to laxatives before enrollment, time to first 
post-dose SBM, and mean number of days per week 
with one or more SBM.
Response rates were significantly higher with 25 mg 
of naloxegol than with placebo (intention–to–treat 
population: study 04, 44.4% vs. 29.4%, P = 0.001; 
study 05, 39.7% vs. 29.3%, P = 0.02; patients with 
an inadequate response to laxatives: study 04, 48.7% 
vs. 28.8%, P = 0.002; study 05, 46.8% vs. 31.4%, 
P = 0.01); in study 04, response rates were also higher 
in the group treated with 12.5 mg of naloxegol (inten-
tion-to–treat population, 40.8% vs. 29.4%, P = 0.02; 
patients with an inadequate response to laxatives, 
42.6% vs. 28.8%, P = 0.03). A shorter time to the first 
post-dose SBM and a higher mean number of days 
per week with one or more SBM were observed with 
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25 mg of naloxegol versus placebo in both studies 
(P < 0.001) and with 12.5 mg of naloxegol in study 
04 (P < 0.001). Pain scores and daily opioid dose 
were similar among the three groups. AE (primari-
ly gastrointestinal) occurred most frequently in the 
groups treated with 25 mg of naloxegol. Treatment 
with naloxegol, as compared with placebo, resulted 
in a significantly higher rate of treatment response, 
without reducing opioid-mediated analgesia [20].
Naldemedine
Naldemedine is an antagonist of the mu, delta, 
and kappa opioid receptors. It acts as PAMORA in the 
GI tract and decrease OIC without reversing analgesia 
which is mediated by the opioid action in the CNS. 
Naldemedine is a derivative of naltrexone with a side 
chain added, which increases the molecular weight 
and the polar surface area and thus reducing its ability 
to cross the blood–brain barrier (BBB) [21].
Pharmcodynamics
In an experimental study the binding affinity and an-
tagonist activity of naldemedine against recombinant 
human µ-, d-, and k-opioid receptors were assayed in 
vitro [22]. Pharmacologic effects of naldemedine were 
investigated using animal models of morphine-in-
duced inhibition of small and large intestinal tran-
sit, castor oil-induced diarrhea, antinociception, and 
morphine withdrawal. Naldemedine showed potent 
binding affinity and antagonist activities for recombi-
nant human µ-, d-, and k-opioid receptors. Naldeme-
dine significantly reduced opioid-induced inhibition 
of small intestinal transit (0.03–10 mg/kg; P < 0.05) 
and large intestinal transit (0.3–10 µmol/L; P < 0.05). 
Naldemedine (0.03–1 mg/kg) pretreatment signifi-
cantly reversed the inhibition of castor oil-induced 
diarrhea by subcutaneous morphine (P < 0.01). Nalde-
medine (1–30 mg/kg) pretreatment (1 or 2 hours) did 
not alter the analgesic effects of morphine in a tail 
flick test in rats, although significant delayed reduc-
tion of the analgesic effect of morphine was seen 
with higher doses of naldemedine (10–30 mg/kg). 
Some centrally mediated and peripherally mediated 
withdrawal signs in morphine-dependent rats were 
seen with naldemedine doses ≥ 3 and ≥ 0.3 mg/kg, 
respectively. Naldemedine displayed potent binding 
affinity to, and antagonistic activity against, µ-, d-, 
and k-opioid receptors. Naldemedine decreased OIC 
in vivo without compromising opioid analgesia [22].
The CNS penetration of naldemedine is negligi-
ble when administered at the recommended dose. 
It is a substrate of the P-glycoprotein (P-gp) efflux 
transporter, which may also decrease naldemedine 
penetration into the CNS. Following a single oral ad-
ministration of [14C]-naldemedine tosylate to rats and 
ferrets little radioactivity was detected in the region 
protected by the BBB. The contribution of P-gp to the 
brain distribution of naldemedine was assessed using 
multidrug resistance 1a/b (mdr1a/b) knockout mice 
[23]. While the brain-to-plasma concentration ratio 
(brain Kp) of naldemedine in the mdr1a/b knockout 
mice was 4-fold of that in the wild-type mice, the 
brain Kp in the mdr1a/b knockout mice was quite 
low (brain Kp < 0.1) suggesting that the low brain 
distribution of naldemedine was due to the limited 
ability to cross the BBB rather than efflux by P-gp and 
therefore brain distribution of naldemedine would 
not be affected by concurrent administration of P-gp 
inhibitors or functional disorder of P-gp [23]. As 
a consequence naldemedine decrease constipating 
effects of opioids without compromising CNS-medi-
ated opioid analgesia.
Pharmacokinetics
Naldemedine is absorbed from GI tract achieving 
peak plasma concentration of approximately 45 minu-
tes in the fasted state. The absolute bioavailability of 
naldemedine is in the range of 20% to 56% without 
clinically significant food effect. The peak plasma con-
centration was reduced by 35% and time to achieve 
peak plasma concentration was delayed from 45 mi-
nutes in the fasted state to 2.5 hours in the fed state, 
whereas no significant difference was observed in 
the area under the plasma concentration-time curve 
by food intake. Thus, naldemedine can be taken 
with or without food. Naldemedine is highly bound 
to predominantly albumin and to a lesser extent to 
alfa1-acid-glycoprotein and gamma-globulin, with 
a mean protein binding ration of 93.2%. The volume 
of distribution equals approximately 155 litres [24].
Naldemedine is metabolized by CYP3A to nor–nal-
demedine, with a minor contribution from UGT1A3 to 
form naldemedine-3-glucuronide (N-3-G). The main 
metabolite in is nor-naldemedine, with a relative 
exposure compared to naldemedine of approximately 
9 to 13%. N-3-G is a minor metabolite, with a relative 
exposure to naldemedine of less than 3%. Naldeme-
dine also undergoes cleavage in the GI tract to form 
benzamidine and naldemedine carboxylic acid.
Naldemedine does not inhibit or induce most 
CYP enzymes (including CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A, 
or CYP4A11 isozymes) and does not inhibitor major 
transporters, thus it probably does not affect the 
pharmacokinetics of concurrently administered drugs.
The elimination half-life of naldemedine is ap-
proximately 11 hours, and the total clearance (CL/F) 
of naldemedine is 8.4 L/h. Naldemedine is excreted 
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in urine and faeces with approximately 20% of the 
naldemedine dose excreted unchanged in urine [4]. 
The peak plasma concentration and area under the 
plasma concentration–time curve increased in an al-
most dose-proportional manner within the dose range 
of 0.1 to 100 mg. A slight accumulation (1 to 1.3-fold) 
for peak plasma concentration and area under the 
plasma concentration-time curve was observed after 
once daily multiple dose administration in the fasted 
state for 10 days.
Mild, moderate and severe renal impairment and 
dialysis does not affect significantly naldemedine 
pharmacokinetics. A mild and moderate hepatic impa-
irment does not significantly affect naldemedine phar-
macokinetics. However, patients with severe hepatic 
impairment were not studied, therefore naldemedine 
is not recommended in this patient group [25].
Adverse effects
The most commonly reported adverse reactions 
in patients with chronic non–cancer pain and OIC 
were abdominal pain (7.8%), diarrhea (5.9%), nausea 
(3.6%), and vomiting (1.1%). The majority of these GI 
adverse reactions were of mild to moderate severity 
and resolved without discontinuation of naldemedine 
treatment. One serious case of abdominal pain and 
one serious case of nausea were reported in patients 
with chronic non-cancer pain and OIC. The most 
commonly reported adverse reactions in patients with 
cancer and OIC were diarrhea (24.5%) and abdominal 
pain (3.9%). The majority of these gastrointestinal 
adverse reactions were of mild to moderate severity 
and resolved with treatment. Two serious cases of 
diarrhea were reported in patients with cancer and 
OIC [26].
Naldemedine is indicated for the treatment of 
opioid–induced constipation (OIC) in adult patients 
who have previously been treated with a laxative. 
Contraindications comprise hypersensitivity to the 
active substance or to any of the excipients of tablet. 
Patients with known or suspected GI obstruction or 
perforation or patients at increased risk of recurrent 
obstruction, due to the potential for GI perforation 
[26]. Patients should be monitored for the develop-
ment of severe, persistent or worsening abdominal 
pain. If obstruction or perforation are suspected, 
naldemedine must be discontinued.
Caution should be exercised with regards to opioid 
withdrawal. Patients should be advised to discontinue 
naldemedine and to contact their physician if opioid 
withdrawal occurs. Cases of possible opioid withdra-
wal syndrome have been reported in the naldemedine 
clinical program. Patients having disruptions to the 
blood–brain barrier such as primary brain primary 
malignancies, brain metastases or other inflamma-
tory conditions, active multiple sclerosis and advan-
ced Alzheimer’s disease may be at increased risk of 
opioid withdrawal or reduced analgesia. The overall 
benefit-risk of naldemedine should be considered in 
these patients with close monitoring for symptoms 
of opioid withdrawal.
The use of naldemedine during pregnancy may 
precipitate opioid withdrawal in a neonate due to 
the immature fetal blood brain barrier. Naldemedine 
should not be used during pregnancy unless the clini-
cal condition of the woman requires treatment with 
naldemedine. It is unknown whether naldemedine and 
its metabolites are excreted in human milk, although 
naldemedine is excreted in milk in rats. At therapeutic 
doses, most opioids are excreted into breast milk in 
minimal amounts. There is a theoretical possibility 
that naldemedine provokes opioid withdrawal in 
a breast-fed neonate whose mother is taking an opioid 
receptor agonist, thus naldemedine should not be 
used during breast-feeding [6].
Overview of naldemedine clinical studies
Based on the results of phase II studies 0.2 mg 
naldemedine was selected as an optimal dose of phase 
III clinical studies [27, 28].
Studies in non-cancer patients
Two phase III randomized, double-blind, pla-
cebo-controlled clinical trials (COMPOSE-I, NCT 
01965158; COMPOSE-II, NCT 01993940) were con-
ducted to assess the efficacy and safety of a daily 
dose of 0.2 mg naldemedine [29]. Adults on a stable 
opioid regimen who discontinued prior laxatives were 
randomized based on their baseline opioid consump-
tion. Patients received active treatment for 12 weeks, 
with subsequent monitoring for an additional 
4 weeks. Based on an intention-to-treat population, 
COMPOSE-I (273 patients naldemedine; 272 placebo) 
and COMPOSE-II (276 patients naldemedine; 274 pla-
cebo) tested a durable response endpoint defined 
as ≥ 3 SBM per week and an increase of ≥ 1 SBM per 
week from baseline for at least nine of the 12 treat-
ment weeks, inclusive of at least three of the last 
4 weeks. In both studies, there were significantly 
more responders in the naldemedine group compared 
to placebo (COMPOSE-I: 47.6 vs. 34.6%, P = 0.002, 
COMPOSE-II: 52.5 vs. 33.6%, P < 0.0001). There 
were also significant increases in the mean frequency 
of SBM per week from baseline to the last 2 weeks 
of treatment in favor of naldemedine (COMPOSE-I: 
least square mean increase 3.42 ± 0.193 [standard 
error] vs. 2.12 ± 0.192, P < 0.0001, and COMPOSE-II: 
3.56 ± 0.174 vs. 2.16 ± 0.174, P < 0.001). In both 
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studies, there were similar numbers of AE in both 
groups (COMPOSE-I: 49 vs. 45% and COMPOSE-II: 
50 vs. 48%). A higher proportion of treatment-related 
adverse effects (TRAE) were noted in the naldemedine 
groups relative to placebo in both studies (COMPOSE-I: 
22 vs. 17% and COMPOSE-II: 20 vs. 11%). The most 
frequently reported AE were diarrhea (COMPOSE-I: 
7 vs. 3% and COMPOSE-II: 9 vs. 2%) and abdominal 
pain (COMPOSE-I: 6 vs. 2% and COMPOSE-II: 5 vs. 1%). 
Two major cardiovascular AE were documented, one 
in a treatment patient in COMPOSE-I and one in 
a placebo patient in COMPOSE-II. One patient re-
ceiving naldemedine in the COMPOSE-II study died 
from an opioid overdose leading to cardiopulmonary 
arrest. Three patients in COMPOSE-I (two naldemedine 
and one placebo) experienced symptoms of opioid 
withdrawal [29].
The final Phase III trial (COMPOSE-III, NCT 
01965652) was a 52-week multicenter randomized, 
double-blind, placebo-controlled study evaluating the 
long-term efficacy and safety of once daily 0.2 mg 
naldemedine [30]. The study population consisted of 
adults with OIC on stable doses of opioids, who may 
or may not have been on other laxatives. The primary 
outcome was safety and tolerability of naldemedine. 
Secondary endpoints assessed naldemedine efficacy. 
A total of 620 naldemedine and 620 placebo patients 
were included in the safety analysis. There were similar 
treatment-emergent adverse effects (TEAE) in each 
group (68.4 vs. 72.1%, respectively). TEAE that oc-
curred in > 5% of patients and with a higher frequen-
cy in naldemedine than placebo groups included ab-
dominal pain (8.2 vs. 3.1%), diarrhea (11.0 vs. 5.3%), 
and vomiting (6.0 vs. 3.1%). No associations between 
naldemedine and opioid withdrawal or decreased an-
algesia were evident. Patients in the treatment group 
had more frequent bowel movements (BM) per week, 
and this difference was statistically significant at all 
measured time points including at 52 weeks [30].
In two open-label, single-arm, Phase III studies, 
the safety and efficacy of naldemedine was assessed 
in Japanese patients with OIC receiving regular-use 
opioids (COMPOSE-6) or PR oxycodone (COMPOSE-7) 
for chronic noncancer pain [31]. Eligible Japanese 
adults with OIC and chronic noncancer pain received 
once-daily oral naldemedine 0.2 mg for 48 weeks, ir-
respective of food intake. Primary end points included 
measures of TEAE, pain intensity, and opioid with-
drawal. Secondary efficacy end points were evaluated 
at treatment week 2. PAC-SYM and PAC-QOL scores 
were evaluated in both 48-week studies.
Of patients enrolled in COMPOSE-6 (N = 43) and 
COMPOSE-7 (N = 10), TEAE were reported in 88% 
(95% CI 74.9–96.1) and 90% (95% CI 55.5–99.7), 
respectively. The most frequently reported TEAE, na-
sopharyngitis and diarrhea, were mostly mild or mod-
erate in severity. Assessments of pain intensity and 
opioid withdrawal remained stable over the 48-week 
treatment periods of both studies. The proportion of 
SBM responders at week 2 in COMPOSE-6 was 81.0% 
(95% CI 65.9–91.4) and 90.0% (95% CI 55.5–99.7) in 
COMPOSE-7. Significant and sustained improvements 
in PAC-SYM and PAC-QOL scores were also observed 
in both studies (all p < 0.05). AE of naldemedine were 
mostly mild or moderate in severity, and the results 
suggest that naldemedine improve bowel function 
and QOL in Japanese patients with OIC receiving 
regular-use opioids or PR oxycodone for chronic non-
cancer pain [31].
In an exploratory analysis [32], the onset of action 
of naldemedine was evaluated in two phase 3, ran-
domized, placebo-controlled trials [29]. Proportion 
of patients experiencing a SBM within 24 hours of 
treatment initiation, time from initial dose to first SBM 
and weekly SBM frequency were assessed. Naldeme-
dine was associated with significant increases in the 
proportion of patients experiencing SBM at 4, 8, 12, 
and 24 hours after the initial dose compared with 
placebo (all P < 0.0001). Within 24 hours in both 
studies, statistically significantly (P < 0.0001) more 
patients treated with naldemedine compared with 
placebo experienced an SBM (61.2% vs. 28.3% and 
56.5% vs. 33.6%, respectively). Median times to first 
SBM were significantly shorter in the naldemedine 
group vs. placebo (COMPOSE-1, 16.1 vs. 46.7 hours; 
COMPOSE-2, 18.3 vs. 45.9 hours; P < 0.0001). Nalde-
medine was also associated with significant increases 
in weekly SBM frequency vs. placebo within 1 week 
(P < 0.001). Most common TEAE were GI-related 
(abdominal pain, diarrhea, and nausea). TEAE were 
reported most frequently on day 1, followed by a de-
crease from days 2 to 7. Naldemedine had a timely 
onset of effect, and GI adverse events largely resolved 
within the first week. These findings should assist 
clinicians counseling patients with chronic noncancer 
pain on expectations when initiating naldemedine 
for OIC [32].
Studies in cancer patients
A phase III trial consisted of a 2-week, random-
ized, double-blind, placebo-controlled study (COM-
POSE-4) and an open-label, 12-week extension study 
(COMPOSE-5) [33]. In COMPOSE-4, eligible adults 
with OIC and cancer were randomly assigned on 
a 1:1 basis to receive once-daily oral naldemedi-
ne 0.2 mg or placebo. The primary end point was 
the proportion of spontaneous bowel movement 
(SBM) responders (≥ 3 SBM/week and an increase 
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of ≥ 1 SBM/week from baseline). The primary end 
point of COMPOSE-5 was safety.
In COMPOSE-4, 193 eligible patients were ran-
domly assigned to naldemedine (n = 97) or place-
bo (n = 96). The proportion of SBM responders in 
COMPOSE–4 was significantly greater with naldeme-
dine than with placebo (71.1% [69 of 97 patients] 
vs. 34.4% [33 of 96 patients]; P < 0.0001). A greater 
change from baseline was observed with naldemedine 
than with placebo in the frequency of SBMs/week 
(5.16 vs. 1.54; P < 0.0001), SBM with complete bowel 
evacuation/week (2.76 vs. 0.71; P < 0.0001), and SBM 
without straining/week (3.85 vs. 1.17; P = 0.0005). 
In COMPOSE-4, more patients treated with nalde-
medine than with placebo reported TEAE (44.3% 
[43 of 97 patients] vs. 26.0% [25 of 96 patients]; 
P = 0.01); in COMPOSE-5, 105 (80.2%) of 131 of 
patients reported TEAEs. Diarrhea was the most fre-
quently reported TEAE in COMPOSE-4 (19.6% [19 of 
97 patients] vs. 7.3% [seven of 96 patients] with 
naldemedine vs. placebo) and COMPOSE-5 (18.3% 
[24 of 131 patients] with naldemedine). Naldemedine 
was not associated with signs or symptoms of opioid 
withdrawal and had no notable impact on opioid-me-
diated analgesia. Once-daily oral naldemedine 0.2 mg 
effectively treated OIC and was generally well tolerat-
ed in cancer patients with OIC [33].
In another report [34] results from secondary end 
points, including quality of life (QOL) assessments 
from a phase III, double–blind study (COMPOSE-4) 
and its open-label extension (COMPOSE-5) [33] was 
presented [34].
In COMPOSE-4, eligible adults with OIC and cancer 
were randomly assigned 1:1 to receive once daily oral 
naldemedine 0.2 mg (n = 97) or placebo (n = 96) 
for 2 weeks, and those who continued on to COM-
POSE-5 received naldemedine for 12 weeks (n = 131). 
Secondary assessments in COMPOSE-4 included the 
proportion of complete SBM (CSBM) responders, 
SBM or CSBM responders by week, and subjects 
with ≥ 1 SBM or CSBM within 24 h postinitial dose. 
Changes from baseline in the frequency of SBMs or 
CSBMs per week were assessed at weeks 1 and 2. Time 
to the first SBM or CSBM postinitial dose was also 
evaluated. In both studies, QOL impact was evaluated 
by PAC-SYM and PAC-QOL questionnaires.
Naldemedine improved bowel function for all 
secondary efficacy assessments versus placebo (all 
P ≤ 0.0002). The timely onset of naldemedine activity 
versus placebo was evidenced by median time to 
the first SBM (4.7 h vs. 26.6 h) and CSBM (24.0 h 
vs. 218.5 h) postinitial dose (all P < 0.0001). In COM-
POSE-4, significant differences between groups were 
observed with the PAC–SYM stool domain (P = 0.045) 
and PAC-QOL dissatisfaction domain (P = 0.015). In 
COMPOSE-5, significant improvements from baseline 
were observed for overall and individual domain 
scores of PAC-SYM and PAC-QOL. Naldemedine pro-
vided effective and timely symptomatic relief from 
OIC and improved the QOL of subjects with OIC and 
cancer [34].
In a post-hoc, pooled, subgroup analysis [35] of 
two randomized studies [28, 33] baseline character-
istics was evaluated that may influence the efficacy 
and safety of naldemedine in patients with OIC and 
cancer [35]. Data for patients who received 0.2 mg 
naldemedine or placebo were pooled from random-
ized, placebo-controlled, phase IIb and phase III stud-
ies. Proportions of SBM responders and patients with 
diarrhea were assessed for each treatment group. For 
the patient subgroups with or without possible BBB 
disruptions, changes in Numerical Rating Scale (NRS) 
and Clinical Opioid Withdrawal Scale (COWS) scores 
were assessed.
A total of 307 patients were included in this analy-
sis (naldemedine: 155; placebo: 152). The pooled pro-
portion of SBM responders was 73.5% with naldeme-
dine vs. 35.5% with placebo. There was a significant 
increase in the proportion of SBM responders with 
naldemedine vs. placebo 38.0% (95% CI 27.6–48.4%; 
p < 0.0001). Greater proportions of SBM responders 
and patients who experienced diarrhea were observed 
with naldemedine vs. placebo in all subgroups. Chang-
es from baseline in NRS and COWS scores were similar 
with naldemedine or placebo in patients with or 
without brain metastases [35].
Although not powered to detect statistically sig-
nificant differences in treatment effect among sub-
groups, this study demonstrated that naldemedine 
appeared to benefit cancer patients with OIC and 
cancer, irrespective of baseline characteristics, and 
did not seem to affect analgesia or withdrawal even 
in patients with potential BBB disruptions. Baseline 
characteristics did not appear to affect the incidence 
of diarrhea in patients who received naldemedine [35].
Summary
OIBD and OIC are common complication in pa-
tients receiving long–term opioid therapy. Any inter-
vention should always be preceded with a meticu-
lous assessment of the OIC taking into account the 
underlying disease, co-morbidities and a thorough 
patient’s assessment including non-medical problems 
[36]. A significant progress has been made with tar-
geted therapies for the management of patients with 
symptoms of OIC and OIBD, namely OXN, MNTX and 
PAMORA designed for oral route of administration 
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such as naloxegol and naldemedine [37–39]. Expert 
Group of the European Society of Medical Oncology 
and Polish Association for Palliative Medicine recom-
mend a consideration of PAMORA in the management 
of OIC [40,41]. Current data from clinical studies 
and systematic reviews indicate that naldemedine is 
an effective and generally well-tolerated treatment 
option for OIC in patients with cancer pain or chronic 
non-cancer pain, with the convenience of once-daily 
oral dosing [42, 43].
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